Research

We are an experienced multi-disciplinary clinical academic team, conducting translational research in the field of thrombosis and haemostasis. Our group’s research is focused on 4 key themes:

Venous Thromboembolism

Research completed under this theme include:

• Understanding specific VTE risk factors, e.g. Ethnicity, HRT, Stroke, Obesity
• Understanding the long-term outcomes of VTE, e.g. the DVT outcomes study
• National VTE prevention work e.g. Mandatory VTE risk assessment
• COVID-19, e.g. COVID-19 and post discharge VTE risk, PE and COVID-19

Currently, under this theme, we have recently completed recruitment and are analysing the findings from the Follow-up In Rivaroxaban patientS in seTting of thromboembolism registry. The aim of the FIRST Registry is to study the incidence of long-term complications (VTE, PTS and CTEPH) for VTE treated with rivaroxaban without bridging heparin (up to 5 years) in routine clinical practice. Links to early findings from FIRST: Experience of rivaroxaban in the obese

Women's health 

Research completed under this theme include:

• Pharmacokinetics of enoxaparin during the antenatal period
• Exploring the prothrombotic phenotype of mode of delivery and its impact on VTE risk
• Understanding women’s experiences and adherence to LMWH during pregnancy and the postnatal period
• Reporting an increased risk of heavy menstrual bleeding with rivaroxaban
• Exploring the distribution of DOACs into breast milk

Currently the following study is being undertaken under this theme:

Abnormal uterine bleeding in women PrescribEd anticoagulant theRapy – understandIng wOmen’s experiences and Developing a consensus on management – the PERIOD study

Acquired bleeding states

Research completed under this theme include:

• Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation
• Whole blood thrombin generation in liver cirrhosis
• The prothrombotic effectof FFP and platelet transfusion in liver disease

The safe and effective use of anticoagulants

Research completed under this theme include:

• Understanding patients adherence, illness beliefs, experiences and medication beliefs when prescribed warfarin and DOACs
• Use of DOACs in special populations, e.g. patients with HIV and newly diagnosed multiple myeloma
• Sharing experience of how best to manage DOACs during dentoalveolar surgery
• Developing a pharmacokinetic model for rivaroxaban from a heterogenous anticoagulation clinic population